MedTrace Logo

Interventional Study on DEterminants and Factors of Physical ACtivity After Treatments in Oncology

NCT05354882 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2023-05-09

No results posted yet for this study

Summary

Benefits of physical activity (PA) as supportive care in cancer have been widely demonstrated by the scientific community. However, survivors who have completed chemo-radio-immunotherapy treatments doesn't achieve PA recommendations on average. This reinforces the need to identify factors influencing PA level, and to propose a multilevel model (macro-, meso-, micro-level) to understand better what facilitates the adoption and maintenance of active behaviour and what hinders it. To date, there is no ecological model in France explaining this behaviour in the post-treatment phase of breast, colorectal, prostate, and lung cancers. From this initial model, we seek to design an educational and motivational intervention in PA.

Thus, the investigators propose to test the feasibility of implementing an individualized program to increase and maintain level of physical activity and to decrease sedentary behaviours in physically inactive cancer survivors. This program is based through and identification of barriers and facilitators of an active lifestyle among this population.

Conditions

Interventions

BEHAVIORAL

Physical activity program

The single group will access to the twelve-week DEFACTO program containing one adapted physical activity session, two discussion group sessions and several motivational interviewing

Sponsors & Collaborators

  • Ligue contre le cancer, France

    collaborator OTHER

  • Garmin International

    collaborator INDUSTRY

  • Stimulab

    collaborator UNKNOWN

  • Université Sorbonne Paris Nord

    lead OTHER

Principal Investigators

  • Aude-Marie AF Foucaut · Université Sorbonne Paris Nord, Laboratoire Educations et Promotion de la Santé UR3412

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-29
Primary Completion
2023-07-31
Completion
2023-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05354882 on ClinicalTrials.gov